Archive

14 October 2009
Update on Commercialisation Process for CVac™ Ovarian Cancer Treatment Vaccine >>

9 October 2009
Change in Substantial Holding >>

9 October 2009
Appendix 3B & Section 708A Notice >>

7 October 2009
Response to ASX Price Query >>

6 October 2009
Appendix 3B >>

29 September 2009
Annual Report to shareholders >>

25 September 2009
Response to an ASX Price Query >>

21 September 2009
Change in substantial holding >>

17 September 2009
Change of Director's Interest Notice - AG MR RH >>

17 September 2009
Appendix 3B >>

10 September 2009
Appendix 3B and Section 708A Notice >>

2 September 2009
South Korean Patent for Oncomab Cancer Antibody Treatment >>

31 August 2009
Prima Secures US FDA Clearance >>

27 August 2009
Preliminary Final Report >>

20 August 2009
Response to an ASX Price Query >>

19 August 2009
Appendix 3B >>

19 August 2009
Change of Director's Interest Notice - AG MR RH >>

11 August 2009
Section 708A Notice >>

11 August 2009
Presentation for Investor Briefing >>

11 August 2009
Teleconference for Investor Briefing >>

11 August 2009
Change of Director's Interest Notice - AG MR RH >>

11 August 2009
Appendix 3B >>

05 August 2009
Results of Adjourned General Meeting >>

30 July 2009
Prima Biomed Submits CVAC IND Application with US FDA >>

23 July 2009
Letter to Shareholders >>

21 July 2009
Appendix 3B and Section 708A Notice >>

21 July 2009
Prima Completes AUD$25.5M Financing >>

17 July 2009
Trading Halt Request >>

8 July 2009
Former Pfizer Head to Run US Trials >>

3 July 2009
Response to ASX Query - Change of Director's Interest Notice >>

3 July 2009
Notice of Adjourned General Meeting >>

1 July 2009
Becoming a Substantial Holder >>

30 June 2009
Appendix 3B and Section 708A Notice >>

30 June 2009
Change of Director's Interest Notice - RH >>

29 June 2009
Completion of Share Purchase Plan >>

29 June 2009
Appendix 3B >>

26 June 2009
Results of Meeting >>

25 June 2009
Postponement of 3 Resolutions >>

5 June 2009
Appendix 3B >>

22 May 2009
Appendix 3B >>

22 May 2009
Notice of Extraordinary General Meeting/Proxy Form >>

15 May 2009
Share Purchase Plan Offer >>

11 May 2009
Appendix 3B >>

11 May 2009
North American Investment Partners >>

1 May 2009
Change of Director's Interest Notice - AG >>

30 April 2009
Appendix 4C - Quarterly >>

28 April 2009
Company Update >>

22 April 2009
Replacement Section 708A Notice >>

22 April 2009
Chinese Patent for Oncomab Cancer Antibody Treatment >>

21 April 2009
Appendix 3B & Section 708A Notice >>

21 April 2009
Investor Presentation >>

17 April 2009
Appendix 3B >>

16 April 2009
Response to an ASX Price Query >>

15 April 2009
Change of Director's Interest Notice - MR >>

26 March 2009
Second European Patent for CVac Ovarian Cancer Treatment >>

16 March 2009
Letter to Shareholders >>

13 March 2009
Change of Principal Place of Business >>

11 March 2009
Secures $12M Commercialisation Funding >>

6 March 2009
Commencement of CVac Cancer Therapy Patient Treatment >>

26 February 2009
Half Yearly Report and Accounts >>

30 January 2009
Appendix 4C - Quarterly Cashflow Report >>

7 January 2009
Appendix 3B and Section 708A Notice >>

7 January 2009
Completion of Share Purchase Plan >>

4 December 2008
Share Purchase Plan Offer >>

21 November 2008
Results of Meeting >>

31 October 2008
Appendix 4C - Quarterly >>

23 October 2008
Positive Meeting with US FDA >>

20 October 2008
Notice of Annual General Meeting/Proxy Form >>

17 October 2008
Change of Share Registry >>

13 October 2008
Canadian Patent Granted For Prima Ovarian Cancer Vaccine >>

24 September 2008
Annual Report to Shareholders >>

19 September 2008
Sales of Unmarketable Parcels Complete >>

10 September 2008
Latest Presentation >>

29 August 2008
Preliminary Final Report >>

25 August 2008
US FDA preIND Meeting Request Submitted for CVac Treatment >>

30 July 2008
Quarterly Activity and Cashflow Report >>

21 July 2008
Sale of Unmarketable Parcels of Shares - Letter to Shareholders >>

11 June 2008
Change of Director's Interest Notice x 3 >>

5 June 2008
Appendix 3B >>

5 June 2008
Change of Constitution >>

4 June 2008
Results of Meeting >>

2 June 2008
Latest Presentation >>

30 May 2008
Update on US FDA Pre-IND Meeting for CVac Cancer Treatment >>

22 May 2008
Appendix 3B >>

14 May 2008
Chairman's Letter to Shareholders >>

13 May 2008
Form 603 and 605 from ANZ >>

30 April 2008
Appendix 4C - Quarterly Report >>

29 April 2008
Notice of Extraordinary General Meeting/Proxy Form >>

16 April 2008
Institutional Research Report Commences >>

8 April 2008
Response to ASX Query >>

7 April 2008
ANZ: Opes Prime Disclosure >>

19 March 2008
GAP Analysis Received for US FDA >>

17 March 2008
Appendix 3B >>

11 March 2008
Change in Substantial Holding >>

4 March 2008
Rights Issue Closed >>

28 February 2008
Half Yearly Report and Accounts >>

15 February 2008
Dispatch of Replacement Prospectus >>

11 February 2008
Revised Timetable - Non-Renounceable Rights Issue of Options >>

11 February 2008
Replacement Appendix 3B >>

11 February 2008
Options Replacement Prospectus >>

6 February 2008
Options Prospectus - Change of Issue and Exercise Prices >>

31 January 2008
Appendix 4C - Quarterly Report >>

18 January 2008
Letter to Option Holders re Pro-rata Offer of Options >>

18 January 2008
Timetable - Non Renounceable Rights Issue of Options >>

18 January 2008
Options Prospectus and Appendix 3B >>

17 January 2008
Issue US Patent to Oncomab >>


04/28/2010
Appointment of New Board Member